Allogeneic Haematopoietic Stem Cell Transplant (HSCT) for people of all ages with Sickle Cell Disease (SCD), Commissioning Policiy (CP224), March 2025.pdf (PDF, 595Kb)
Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours, Policy Position Statement (PPS315), November 2025 (PDF, 423Kb)
Autologous haematopoietic stem cell transplantation for people aged 18 years and over with previously treated relapsing multiple sclerosis, Commissioning Policy (CP247), November 2024.pdf (PDF, 523Kb)
Brachytherapy for the treatment of gynaecological malignancies for people aged 18 years and above, Commissioning Policy (CP75), July 2024.pdf (PDF, 440Kb)
Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages), Policy Position Statement (PPS167), September 2025.pdf (PDF, 459Kb)
Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors, Policy Position Statement, (PP189), November 2023.pdf (PDF, 288Kb)
Everolimus for refractory focal onset seizures associated with tuberous sclerosis complex (aged 2 years and above), (PP250), December 2026.pdf (PDF, 258Kb)
Extracorporeal Membrane Oxygenation (ECMO) as a Bridge to Lung Transplant (BTLT) (All Ages), Policy Position Statement, (PP251), February 2023.pdf (PDF, 288Kb)